Ellie Leick

April 20, 2020

In light of the COVID-19 pandemic, transplant-eligible patients with cancer are undergoing careful assessment to determine whether they should proceed with the procedure or receive additional consolidation therapy to buy time, according to Naval G. Daver, MD.

April 17, 2020

Although the emergence of more targeted and immunotherapies continues to expand the melanoma treatment paradigm, surgery remains an important tool in the management of these patients, according to Omid Hamid, MD.

March 28, 2020

Retrospective results showed that African-American women with endometrial cancer are less likely to receive evidence-based care compared with white women—1 factor causing significant racial disparities in endometrial cancer care, explained senior study author Jason D. Wright, MD.

March 12, 2020

Biomarker-driven treatments continue to expand in prostate cancer, as research efforts explore responses across different subgroups, explained Petros Grivas MD, PhD.

February 29, 2020

Autologous stem cell transplantation continues to have a significant role for patients with high-risk myeloma; however, research efforts continue to focus on novel induction, consolidation, and maintenance regimens, as well as the use of tandem transplant, explained Andrew Branagan, MD.

February 02, 2020

The presence of the proteins p16 and p21 has shown to be predictive of treatment response in patients with osteosarcoma, a disease that previously had no identified biomarkers to indicate whether or not patients would benefit from therapy, explained C. Parker Gibbs, MD.

January 25, 2020

Updated data on several emerging treatment modalities were presented at the 2019 ASH Annual Meeting in multiple myeloma, including CAR T-cell therapy, antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and a novel selinexor (Xpovio) combination, explained Sandy W. Wong, MD.

January 14, 2020

Research presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) had a significant effect on the standard of care for patients with HER2-positive metastatic breast cancer, explained Erika P. Hamilton, MD.

January 13, 2020

The standard of care for treatment-naïve patients with advanced renal cell carcinoma (RCC) has shifted from a single-agent VEGF TKI to a checkpoint inhibitor plus either a VEGF TKI or a CTLA-4 inhibitor, explained David F. McDermott, MD.

January 09, 2020

The approval of several TKIs and combination regimens has led to more treatment options for patients with renal cell carcinoma (RCC), with a heavier focus on individualized approaches, explained Ajjai Shivaram Alva, MBBS.